Cancer Letters
Volume 222, Issue 1 , Pages 89-94 , 10 May 2005

Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro

Received 7 July 2004 ,Revised 10 August 2004 ,Accepted 2 September 2004.

References 

  1. Gordon SG, Cross BA. A-factor X-activating cysteine protease from malignant tissue. J. Clin. Invest. 1981;67:1665–1671
  2. Falanga A, Gordon SG. Comparison of properties of cancer procoagulant and human amnion–chorion procoagulant. Biochem. Biophys. Acta. 1985;831:161–165
  3. Gordon SG, Mourad AM. The site of activation of factor X by cancer procoagulant. Blood Coagul. Fibrinolysis. 1991;2:735–739
  4. Gordon SG, Franks JJ, Lewis BJ. Comparison of procoagulant activities in extracts of normal and malignant human tissue. J. Natl Cancer Inst. 1979;62:773–776
  5. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry. 1985;24:5558–5567
  6. Kozwich DL, Kramer LC, Mielicki WP, Fotopoulos SS, Gordon SG. Application of cancer procoagulant as an early detection tumor marker. Cancer. 1994;74:1367–1376
  7. Mielicki WP, Wierzbicki R. Cancer procoagulant in serum of rats during development of experimental epithelioma. Int. J. Cancer. 1990;45:125–126
  8. Mielicki P, Kozwich D, Kramer L, Gordon S. Effect of divalent ions on the activity of cancer procoagulant. Arch. Biochem. Biophys. 1994;314:165–170
  9. Mielicki WP, Tenderenda M, Rutkowski P, Chojnowski K. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett. 1999;146:61–66
  10. Olas B, Wachowicz B, Mielicki WP, Buczynski A. Free radicals are involved in cancer procoagulant-induced platelet activation. Thromb. Res. 2000;97:169–175
  11. Olas B, Wachowicz B, Mielicki WP. Cancer procoagulant and blood platelet activation. Cancer Lett. 2001;169:165–171
  12. Olas B, Wachowicz B, Mielicki WP. Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant. Platelets. 2001;12:431–435
  13. Mielicki WP, Mielicka E, Gordon SG. Cancer procoagulant activity studies using synthetic peptidyl substrates. Thromb. Res. 1997;87:251–256
  14. Mielicki WP, Gordon SG. Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant. Blood Coagul. Fibrinolysis. 1993;4:441–446
  15. Mielicki WP, Sobolewska M. Cancer procoagulant (EC 3.4.22.26): the kinetics of its inhibition by E-64 and modulation of the activity by cadmium, cooper and tin ions. Cancer Res. Ther. Control. 2001;11:135–141
  16. Harlow E, Lane D. Antibodies. A Laboratory Manual. New York: Cold Spring Harbor; 1988;
  17. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47:936–942
  18. Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct. 1988;13:281–292
  19. Tuszynski G, Murphy A. Spectrophotometric quantitation of anchorage-dependent cell numbers using the bicinchoninic acid protein assay reagent. Anal. Biochem. 1990;184:189–191
  20. Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood. 1988;71:870–875
  21. Donati MB, Falanga A, Consonni R, Alessio MG, Bassan R, Buelli M, et al. Cancer procoagulant in acute non-lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb. Haemost. 1990;64:11–16
  22. Rucinska M, Furman M, Skrzydlewski Z, Zaremba E. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Acta Biochim. Pol. 1997;44:109–112
  23. Gordon SG, Tagawa M. The cytotoxic effect of cancer procoagulant antibodies on H345 small lung carcinoma cells. Cancer Res. 1993;34:453
  24. Kramer LC, Drisko J, Gordon SG. Anti-metastatic effects of anti-CP antibodies in the B-16 melanoma murine model. Proceedings of the Annual Session University of Colorado Cancer Control. vol. 3. 1993;p. 53
  25. Olas B, Mielicki WP, Wachowicz B, Krajewski T. Cancer procoagulant stimulates platelet adhesion. Thromb. Res. 1999;94:199–203
  26. Kawabata A, Kuroda R. Protease-activated receptor (PAR), a novel family of G protein-coupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. Jpn. J. Pharmacol. 2000;82:171–174
  27. Lafrenie RM, Yamada KM. Integrin-dependent signal transduction. J. Cell. Biochem. 1996;61:543–553
  28. Tang DG, Honn KV. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis. 1995;14:109–122
  29. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569–571

PII: S0304-3835(04)00710-4

doi: 10.1016/j.canlet.2004.09.005

Cancer Letters
Volume 222, Issue 1 , Pages 89-94 , 10 May 2005

Article Tools

* Image Usage & Resolution